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INTRODUCTION 
 
Ischemic heart disease is one of the major causes of morbidity and 
mortality all over the world.  Various medical and surgical strategies have been 
evolved to reduce the mortality from acute MI which includes the use of 
thrombolytic agents, β blockers, ACE inhibitors, antioxidants, PTCA and 
Coronary artery bypass surgery (CABG). CABG is still considered the gold 
standard. Many reports have shown that upto 90% of patients undergoing 
CABG surgery experience a fall in ejection fraction and cardiac index during 
the immediate post-operative period. This has been attributed to various 
factors of which ischemia associated with aortic cross clamping and 
inadequate myocardial protection during surgery seem to be the main causes. 
One intervention for myocardial preservation which has received universal 
acceptance and generated a lot of excitement is the phenomenon of 
“Myocardial Ischemic preconditioning”. Myocardial preconditioning can be 
achieved by various methods. Recently several studies have reported 
cardioprotective effects of volatile agents in coronary surgery patients. This 
has been achieved with different volatile agents like halothane, enflurane, 
isoflurane and sevoflurane. Isoflurane and recently sevoflurane have been 
shown to be better preconditioning agents in some studies. My study is an 
attempt to determine if administration of either isoflurane or sevoflurane in 
  7
patients undergoing CABG surgery will improve postoperative myocardial 
contractility and function and also to determine which of these volatile agents 
would offer more cardiac protection when used as preconditioning and post 
conditioning agents throughout surgery including the cardio pulmonary bypass 
period. 
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AIM 
     
To compare the cardioprotective properties of Isoflurane and 
Sevoflurane when used before, during and after Cardiopulmonary bypass 
(CPB) to improve postoperative outcome in coronary artery bypass graft 
surgeries by analyzing:  
    
A) Hemodynamic parameters such as Invasive arterial blood 
pressure, Electrocardiogram, Cardiac index, Systemic vascular 
resistance and Central Venous pressure. 
 
B) Postoperative measurements of Creatinine kinase-MB to 
compare  degree of ischemia 
 
C) Markers of Oxidative and nitrosative stress such as protein 
carbonyl content, malondialdehyde, protein thiols, total thiols and 
nitrates. 
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REVIEW OF LITERATURE 
Purpose:  
Our literature search is mainly stressed on the mechanism of 
myocardial ischemia, myocardial dysfunction both short and long term after 
bypass and ischemic reperfusion injury (IRI).  We reviewed the main products 
utilized in the oxidative reaction and the byproducts of oxidative stress 
conditions. We also reviewed the methods by which IRI can be minimised or 
prevented, which involved mainly preconditioning the myocardium before the 
actual ischemic episode.  The various techniques and agents that have been 
used to achieve this have been extensively reviewed especially the role of 
volatile anesthetic agents. Also the importance of timing the preconditioning 
agent, whether early or late preconditioning would help in minimising the 
detrimental effects and prevent neutrophil activation associated with IRI.  Also 
the various biochemical and cardiac markers that would be most suitable and 
useful in designing our study were also reviewed. 
 
 
Myocardial ischemia 
Acute occlusion or  progressive constriction of a coronary artery causes 
reduction or abolition of systolic shortening and thickening of the ischemic wall 
(1). Ischemic segments also demonstrate paradoxical wall motion (termed 
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post systolic shortening or post systolic thickening). These functional changes 
relate directly to the reduction in coronary blood flow. 
 
Mechanism of Myocardial ischemia 
The time course of the effects of ischemia on cardiac tissue is well 
known. There is a marked reduction of contractile function resulting from 
decreased ATP production a few seconds after the onset of ischemia. 
Leakage of potassium ions is responsible for the alteration of ST segments. 
Within minutes an intracellular acidosis develops associated with an increase 
in myoplasmic calcium and the beginning of cell swelling (2). Later, cellular 
lesions become irreversible. The ultra structure of the cells becomes altered 
and macromolecules (CK-MB, Troponins) are released. An increased 
concentration of cytosolic and mitochondrial calcium plays a central role in the 
damage to the cells and their membranes. 
 
Myocardial ischemia occurs in the presence of fixed or dynamic 
coronary artery stenosis. The main cause of ischemia in fixed coronary 
stenosis includes tachycardia, excessive left ventricular filling and hypoxemia. 
In dynamic stenosis, in addition to the above mentioned factors, activation of 
sympathetic and parasympathetic systems are also involved. Moreover 
several endothelium derived mediators may enhance vasoconstriction (3). 
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Myocardial stunning (flow-contractility mismatch) 
The term myocardial stunning was coined by Brownwald and Kloner (4) 
in 1982 to describe a reduction in function after a brief period of ischemia 
followed by reperfusion. The impairment of action could last for several hours 
to days at a time when coronary blood flow was normal and there was no 
obvious cellular damage. During the perioperative period a high proportion of 
adult patients suffer from episodes of myocardial ischemia, most of which are 
silent but can be prolonged. Importantly, silent myocardial ischemia is 
supposed to be a common cause of myocardial stunning and is a predictor of 
adverse cardiac outcome. 
 
 
Mechanism of myocardial stunning 
Myocardial ischemia followed by reperfusion causes reversible or 
irreversible damage depending on its duration. In stunning ischemic damage 
is, in principle reversible (5). 
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Three main mechanisms are involved in the establishment of stunned 
myocardium: 
a) formation of free oxygen radicals 
b) accumulation of intracellular calcium 
c) Degradation of contractile proteins. 
 
Free radicals do not have a single target, but adversely affect many 
components of the cell including sarcolemmal and sub cellular membranes of 
organelles.  The role of free radicals in stunning is confirmed by the improved 
post-ischemic functional recovery in the presence of super oxide dismutase(6). 
 
During ischemia and the early phase of reperfusion, there is an 
increase in the concentration of intracellular Ca2+. Calcium overload can 
decrease the sensitivity of contractile proteins to Ca2+, thus diminishing the 
developed force. Calcium overload may result from altered Na+/Ca2+ antiport 
and from altered Ca2+ fluxes at the level of sarcoplasmic reticulum. Such 
alteration in calcium handling may be attributable to ischemia induced 
intracellular acidosis. 
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Myocardial Hibernation 
The concept of myocardial hibernation was put forward by Rahimtoola 
in 1985(7, 8). In the hibernating myocardium, myocardial function is 
diminished as a consequence of insufficient coronary blood flow. However this 
reduction is not necessarily permanent: an improved balance of supply and 
demand may augment myocardial function (9, 10). The issue of myocardial 
hibernation is clinically important because the risk of adverse cardiac outcome 
in cardiac and non cardiac surgery increases with the reduction of the ejection 
fraction. 
 
 
Mechanism of Myocardial hibernation 
In hibernating myocardium, cardiac metabolism is down regulated. It 
has been proposed that abolition of contractility of hibernating cardiac tissue is 
attributable to chronic stunning caused by multiple episodes of severe 
ischemia followed by repetitive reperfusion. Other experimental models 
suggest that hibernation occurs as a result of chronic low flow state. In either 
case, hibernating myocardium should be salvageable by restitution of an 
adequate coronary blood flow. 
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Myocardial Preconditioning 
In 1986 Reimer (11) and colleagues reported that a brief period of 
ischemia decreased the rate of ATP depletion during the further period of 
ischemia. Murry and colleagues (12) reported that brief periods of ischemia 
made the heart more resistant to infarction during subsequent periods of acute 
coronary occlusions, reducing the infarct size by 70-80%. This phenomenon, 
termed myocardial preconditioning is the most powerful means of achieving 
cardiac protection. It can be defined as 
 “An adaptive mechanism by which a brief period of reversible ischemia 
increases the heart’s tolerance to a subsequent longer period of ischemia”. 
Two different time frames have been defined for pre-conditioning – 
early or the “classical pre-conditioning” which involves the activation of various 
membrane receptors and lasts only between 1 & 3hour and a late 
phenomenon – which is termed as the “second window” of protection begins 
12-24 hours later and lasts for up to 72 hours and is called “late or delayed 
preconditioning”(13). 
Preconditioning can result from successive episodes of angina or silent 
myocardial ischemia. Preconditioning also reduces the risk of ischemia 
induced ventricular tachycardia and ventricular fibrillation (14). During 
coronary angioplasty, sequential occlusions cause fewer anginas, smaller ST-
segment changes and lesser lactate production (15). The damage occurs not 
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during the period of tissue ischemia but during the period of reperfusion. This 
injury is termed as  
Ischemic Reperfusion Injury (IRI) and is responsible for paradoxical 
organ death and dysfunction after termination of the reperfusion period. The 
mechanism involved in IRI include 
a) Reduction in high energy phosphate (ATP) levels for many hours after  
 tissue ischemia. 
b) Pro-inflammatory cell (neutrophilis and mast cells) mediated cellular  
and micro vascular injuries, through direct cellular toxicity of super 
oxide free radicals that are generated by these cells during ischemia 
and subsequent reperfusion.  
c) Micro vascular dysfunction with platelet plugging and endothelial  
damage resulting in a no-reflow phenomenon with inadequate tissue 
perfusion during the reperfusion period. 
d) Calcium overload mediated reperfusion 
Ischemic stimuli cause the release of stress mediators such as 
adenosine, bradykinin, nor epinephrine and opioids. The mechanisms of 
preconditioning involve several types of triggers and mediators. Among them 
adenosine, bradykinin/opioid and adrenoceptors play an important role. Via G-
proteins, phospholipase C and proteinkinase C, these receptors act on 
mitochondrial and sarcolemmal potassium ATP channels and calcium 
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channels. In order for ischemic or pharmacologic preconditioning to occur, it is 
necessary to reach an activation threshold. This threshold represents the sum 
of the activity of several mediators. 
Role of Adenosine (ADO) 
The role of adenosine in preconditioning has been well documented. 
Adenosine A1-receptor activation plays an important role. These receptors 
are coupled with K+ATP channels (16) via Gi-proteins. Activation of adenosine 
receptors decreases the production of reactive oxygen species and 
attenuates myocardial stunning (17). Adenosine does not protect against 
Ischemic reperfusion injury when administered at the time of reperfusion, 
which indicates that Adenosine receptor activation must precede prolonged 
ischemia (18, 19). The protective mechanisms of adenosine in Ischemic 
preconditioning have been thought to be by 
a) better preservation of tissue ATP 
b) inhibition of neutrophil and mast cell activity 
c) antioxidant(22) and anti-free radical activity(21) 
d) anti-platelet activity 
e) inhibition of no reflow phenomenon.(20) 
f) Activation of K+ATP   channels and reduction of calcium intracellularly. 
g) Activation of protein kinase C and 
h) Premature degradation of mast cells.(23,24) 
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Fig 1 . Role of Adenosine in Ischemic preconditioning 
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Adenosine is known to inhibit neutrophil mediated free radical 
production through ADO2 receptor activation (23, 26) and may be responsible 
for limiting the degree of micro vascular injury during ischemia and reperfusion 
by inhibiting free radical mediated damage to endothelial cells and through its 
antiplatelet activity. Adenosine is a potent vasodilator of the vasculature 
ranging from major coronary arteries to microvasculature (18, 27). Adenosine 
in addition opposes the effects of a number of focally released vasoconstrictor 
substances like leucotrines, thrombaxane A2, endothelin and platelet activating 
factor (28). It also inhibits release of nor-adrenaline from the sympathetic 
mechanisms which in turn facilitates regional blood flow in a previously 
ischemic bed (19, 25, 28). 
A3 receptors have been found to be present in mast cell membranes 
and they function to degranulate mast cells. Increased interstitial (29) ADO 
may be responsible for prematurely degranulating these mast cells during the 
preconditioning period. A brief IPC before a more prolonged ischemic period 
may wash out these mast cell products and prevent subsequent mast cell 
mediated tissue damage. It has been documented by Sandhu et al in rabbit 
myocardium that IPC prevented an increase in cAMP levels, which invariably 
occurred during sustained ischemia (30). There is usually an increase in 
intracellular cAMP during myocardial ischemia due to increased interstitial nor 
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epinephrine release and stimulation of α-1 receptors. The blunting of cAMP by 
the IPC may be caused by neither attenuation of nor epinephrine release 
during ischemia. 
 
Role of Volatile agents  
Ischemic preconditioning can also be mimicked by certain volatile 
agents in the myocardium (31-36). Studies on canine models of myocardial 
stunning by Warltier et al (32) have shown that Isoflurane, Halothane or 
Sevoflurane administered during an ischemic period but not during reperfusion 
period correlated with faster recovery of cardiac contractility. This study 
triggered a dramatic proliferation of investigations regarding proliferation 
protection by anesthetics. Volatile agents which are known to mimic IPC 
include isoflurane, sevoflurane, halothane and enflurane.(32,35,36)  
Preconditioning by volatile agents is a promising therapeutic strategy to 
render myocardial tissue resistant to perioperative ischemia. It was 
hypothesized that Sevoflurane preconditioning would decrease postoperative 
release of brain natriuretic peptide, a biochemical marker for myocardial 
dysfunction (37). 
Volatile anesthetics exert significant protection against myocardial 
ischemia (38) and excitotoxic cardiomyocyte death (39). One of the 
mechanisms by which volatile anesthetics induce protection in myocytes is 
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pharmacological preconditioning (40,41), the activation of potent endogenous 
protective mechanism in cardiac tissue against a variety of important stressors.  
   In contrast only a few studies have demonstrated the preconditioning 
effects of volatile agents in human myocardium (42-45). Cardioplegic arrest in 
patients undergoing coronary artery bypass graft (CABG) surgery is one of the 
few controlled models of human myocardial ischemia.  
 
Sevoflurane and Desflurane 
            Further evidence for the protective properties of halogenated 
anesthetics was collected for halothane and isoflurane after 1997 (46-62). A 
new agent whose protection was demonstrated recently is sevoflurane. This 
anesthetic improves post-ischemic mechanical and coronary function and 
reduces infarct size (62-67). A beneficial effect of desflurane was suggested by 
a few groups (51, 66,  67). Further investigations are needed to determine the 
effect of desflurane in other experimental settings. 
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Fig 2. Proposed mechanism(s) underlying sevoflurane (sevo)-induced 
cardioprotection 
 
 
 
 
 
 
 
 
 
 
Protein kinase C (PKC), mitochondrial (Mito) K+ATP, and reactive oxygen species (ROS) all 
contribute to the signal transduction of sevo-induced cardioprotection, suggesting that the 
three signaling elements are interactively arranged within a common signaling pathway. In 
addition, it cannot be excluded that sevo directly modulates G-protein coupled receptors (G-
protein-R), PKC, Mito K+ATP, or ROS. Finally, it was suggested that the cardio protective effect 
results in modulation of the Ca2+ regulation and redox state of the cardiomyocyte.  
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Different approaches to assess myocardial injury 
Several indices other than post-ischemic ventricular mechanical function 
have been examined to asses the degree of myocardial injury in the past few 
years. Reduction in infarct size has been well demonstrated with volatile 
anesthetics (46-48, 51, 55, 56, 58, 67). Results of infarction studies are more 
consistent than those of post-ischemic contractility. Kersten and coworkers 
administered isoflurane to dogs for 1 hour before 60-min LAD occlusion. The 
extent of infarct was reduced from 25% to 12%. According to Cope et al., 
preconditioning with halothane, enflurane or isoflurane diminishes infarct size 
to less than one third in rabbits (47). 
Another approach to evaluate post-ischemic injury of the heart is to 
examine the coronary vasculature. Halothane, Isoflurane and Sevoflurane 
reduced the number of neutrophils sequestered in the coronary vasculature 
after ischemia (49, 54). A similar effect was also shown for platelets. Reduced 
neutrophil/platelet entrapment by anesthetics was accompanied by 
enhancement of post-ischemic mechanical function (49, 54, 62, 64). 
Novalija and coworkers measured coronary flow changes in response to 
endothelial-dependent independent vasodilators. Sevoflurane preserved the 
reaction provoked by both types of vasodilators during the reperfusion period 
and was better than no treatment (65). 
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Mechanisms of protection by halogenated anesthetics 
Before 1997, mechanisms underlying the cardiac protection were 
suggested to be preservation of ATP, reduction in calcium influx to the cell, 
inhibition of free radical formation and activation of K+ATP channels (68). 
Recently, progress in elucidating the mechanisms responsible for protection 
was achieved when investigators related ischemic preconditioning and 
anesthetic induced protection and also examined the coronary system 
 
Preconditioning 
Halogenated anesthetics dilate the coronary arteries via K+ATP channels, 
known to be key constituent of the ischemic preconditioning pathways. Cason 
et al hypothesized that halogenated anesthetics induce an ischemic 
preconditioning-like effect. They studied rabbit hearts in situ treated with 5-min 
coronary occlusion followed by reperfusion. Administration of 15 min isoflurane 
was followed by washout before 30-min coronary occlusion. In the ischemic 
preconditioning group infarction was reduced by 74% compared to the non 
pretreated group and reduced by 30% in the isoflurane group. Although less 
effective than ischemic preconditioning, isoflurane limited ischemic injury even 
though isoflurane was washed-out, i.e. isoflurane had an ischemic 
preconditioning effect (46). These findings indicate that the signals for 
halogenated anesthetics, like for brief periods of ischemia in ischemic 
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preconditioning, are preserved in intracellular components that can mediate 
protection against forthcoming ischemia. The protection by halogenated 
anesthetics can be reversed by a selective adenosine A1 receptor 
antagonist(61), a Gi protein inhibitor (58), PKC inhibitors (47, 59), and K+ATP 
channel blockers (48, 56, 57, 60, 61, 67). Contribution of mitochondrial K+ATP 
channel appears certain (46, 47), but not the sarcolemmal K+ATP channel. 
These observations strongly suggest that halogenated anesthetic agents 
provide protection via a mechanism similar to that of ischemic preconditioning. 
As the protection by halogenated anesthetics is not accompanied by 
augmented release of adenosine (47), it could be assumed that they stimulate 
adenosine receptors via a non adenosine mechanism, or up regulate the 
adenosine receptor G protein complex to promote the signal transduction 
downstream.  
 
Coronary vasculature 
 Halothane, isoflurane and sevoflurane was shown to have reduced 
number of trapped neutrophils in the heart during reperfusion (49,54). The post 
ischemic expression of CD11 which forms an integrin with CD18 was also 
suppressed by volatile anesthetics (54). Kowalski et al showed that neutrophil 
adhesion was attenuated even when sevoflurane was administered only during 
reperfusion (49). These studies imply that halogenated anesthetics can act 
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directly on the neutrophils at the time of reperfusion. Volatile anesthetics also 
reduced platelet adhesion on the vascular wall after ischemia (62, 64) but 
Sevoflurane failed to reduce the expression of glycoprotein 11b/111a, a 
platelet adhesion molecule involved in the platelet-endothelium interaction 
(64). When ischemia is regional, one way to slow the progression of ischemic 
injury is to increase coronary collateral flow. Kersten et al showed that 
sevoflurane selectively increased collateral flow to the ischemic areas in the 
dogs with chronic LAD stenosis. This effect was not reversed by glibenclamide, 
a non-selective K+ATP channel blocker (69). 
Cardiac surgery and some noncardiac procedures are associated with a 
significant risk of perioperative cardiac morbid events. Experimental data 
indicate that clinical concentrations of volatile general anesthetics protect the 
myocardium from ischemia and reperfusion injury, as shown by decreased 
infarct size and a more rapid recovery of contractile function on reperfusion. 
These anesthetics may also mediate protective effects in other organs, such 
as the brain and kidney. Recently, a number of reports have indicated that 
these experimentally observed protective effects may also have clinical 
implications in cardiac surgery. However, the impact of the use of volatile 
anesthetics on outcome measures, such as postoperative mortality and 
recovery in cardiac and noncardiac surgery, is yet to be determined (70). 
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Some of the studies also demonstrated that if the anesthetic was 
stopped more than 30min before the coronary artery was occluded the 
preconditioning effect was lost(70). 
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De Hert and colleagues (71) conducted a randomized study of 320 
elective CABG patients, in which 80 patients received propofol, 80 midazolam , 
80 sevoflurane and 80 desflurane. All patients received a remifentanil - based 
anesthetic regimen. They found a significant decrease in ICU and hospital 
length of stay in the volatile groups when compared with the non-volatile 
groups. Postoperative troponin I and inotrophic support was significantly lower 
in the volatile group.  
 
Neutrophil mediated secretion and activation of matrix MMP-9. 
         Cardiopulmonary bypass (CPB) induces neutrophil activation, 
degranulation and a systemic inflammatory response. Matrix metalloproteinase 
(MMP-9) exists in neutrophils and is released on neutrophil activation. 
Increased levels of MMP-9 have been observed in patients undergoing CPB. 
Plasma levels and activity of MMP-9 increased significantly 2-6hr after 
beginning CPB. CPB caused an increase in the concentration and activity of 
plasma MMP-9 expression and production which suggests that MMP-9 is 
derived primarily from neutrophils and may contribute to the inflammatory 
response associated with CPB (72).  
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Previous studies have investigated the role of volatile anaesthetic 
agents in myocardial protection during coronary artery bypass graft (CABG) 
surgery, and some have identified beneficial effects. However, these studies 
have been too small to identify a significant effect on myocardial infarction (MI) 
or mortality. A systematic overview and meta-analysis of all randomized trials 
comparing volatile with non-volatile anaesthesia in CABG surgery identified 27 
trials that included 2979 patients. There was no significant difference in 
myocardial ischemia, MI, intensive care unit length of stay or hospital mortality 
between the groups (all P>0.05). Post-bypass, patients randomized to receive 
volatile anaesthetics had 20% higher cardiac indices (P=0.006), significantly 
lower troponin I serum concentrations (P=0.002) and lesser requirement for 
inotropic support (P=0.004) compared with those randomized to receive i.v. 
anaesthetics. Duration of mechanical ventilation was reduced by 2.7 h 
(P=0.04), and there was a 1 day decrease in hospital length of stay (P<0.001). 
Some of these outcomes were based on a smaller number of trials because of 
incomplete data, largely because the individual trials focused on one or more 
surrogate endpoints. We found some evidence that volatile anaesthetic agents 
provide myocardial protection in CABG surgery, but larger adequately 
powered trials with agreed, defined outcomes need to be done to fully assess 
a possible beneficial effect of volatile anaesthetic agents on the risk of MI and 
mortality (73). 
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Ecto-5'-nucleotidase activity significantly increased in patients receiving 
isoflurane according to a preconditioning protocol. There is a large body of 
evidence implicating PKC as a critical mediator of the cardioprotective 
response to this preconditioning phenomenon.(75) 
In the human heart, however, such an involvement has, until now, been 
exclusively based on in vitro studies that used cultured cardiomyocytes(76) or 
right atrial trabeculae(77) subjected to "simulated" ischemia/reperfusion (in fact, 
anoxia/reoxygenation) and showed that PKC agonists and antagonists trigger 
or blunt the preconditioning response, respectively. More direct evidence for a 
role of PKC has been the demonstration of the cytosol-to-membrane 
translocation of its -isoform induced through the exposure of human 
cardiomyocytes to adenosine.(76) However, until the assay of the PKC isoforms 
most relevant to cardioprotection can be accurately performed in human 
biopsy samples taken during cardiac surgery, one has to rely on surrogate 
markers like ecto-5'-nucleotidase. This enzyme, which releases adenosine 
from 5'-cAMP, is 1 of the substrates that is phosphorylated by PKC, (78, 79) and 
elevation of its levels therefore stands as a reporter of PKC activation (80). 
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Platelets enhanced the ability of neutrophils to cause coronary 
endothelial dysfunction. This effect was prevented by isoflurane. This may be 
attributable to an inhibitory action on super oxide production by the neutrophils 
leading to reduced expression of endothelial adhesion molecules and in turn 
reduced neutrophil adherence (81). 
 
Oxidative stress, nitric oxide and volatile anesthetic preconditioning  
Ischaemia has been shown to compromise defence mechanisms 
against oxygen free radicals, mainly by decreasing levels of anti-oxidant 
enzymes such as mitochondrial superoxide dismutase and a decreasing tissue 
content of reduced glutathione (GSH). Reperfusion and the concomitant 
increase in oxygen then results in an increased production of free radicals, 
which result in oxidation of thiol groups (GSH and protein thiols) and lipid 
peroxidation 82. Thus, reactive oxygen species (ROS) are central to cardiac 
ischemic and reperfusion injury. They have been implicated in a variety of 
phenomena in this context such as myocardial stunning, infarction and 
apoptosis, and possibly to the genesis of arrhythmias 83. A recent study from 
India also showed that levels of malondialdehyde (a marker of lipid 
peroxidation) were significantly increased in patients with myocardial 
infarction, accompanied by a decrease in activities of anti-oxidant enzymes 
such as superoxide dismutase, catalase and glutathione reductase 84.  
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Nitric oxide is also now emerging as an important signaling molecule, 
and in an animal model of off-pump CABG, it has been shown that circulating 
levels of nitric oxide decrease by 10 minutes after reperfusion, but 
subsequently increase significantly by 24 hours after reperfusion 85. High 
levels of nitric oxide can result in production of nitrosative species such as 
peroxynitrite, which can also produce lipid peroxidation 86. Nitrate was 
measured as a marker for nitric oxide (87). Again, however, the beneficial 
effect of pre-conditioning by volatile anaesthetics has also been shown to 
require nitric oxide 88. Here again the explanation could be differences in 
concentration. High concentrations of nitric oxide have been shown to be 
damaging in a number of contexts, while low levels are generally protective.  
Female gender-induced reductions in infarct size are mediated by 
eNOS, but remote isoflurane exposure (1.0 MAC) before ischemia and 
reperfusion does not produce additional cardio protection in vivo (89). 
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MATERIALS AND METHODS 
This randomized, blinded, clinical controlled trial was approved by the 
Research and ethics committee of our institution. Twenty patients scheduled 
to undergo elective CABG surgery on cardio pulmonary bypass pump for 
coronary artery disease were included in this study. The surgeon, the pump 
technician and biochemist was blinded to the drug, the anaesthetist involved 
with the surgery could not be blinded to the anaesthetic agent.  
EXCLUSION CRITERIA: 
a)   Off pump CABG 
b)   Previous coronary (or) valvular heart surgery 
c)  Preoperative hemodynamic instability requiring medical or                 
mechanical support 
d)  Severe hepatic disease (ALT or AST >150U/L) 
e)  Renal insufficiency (creatinine>1.5mg/dl.)\ 
f)  COPD (FEV1<50% of predicted or <0.8L) 
g)  H/o neurological disturbances. 
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Randomization 
Patients were randomly allocated into group A (isoflurane group) and 
group B (sevoflurane group) using computer generated random numbers. This 
randomization was done before the study began to assure equal allocation to 
the Group A and Group B. The randomization envelope was opened by an 
anesthetist, and accordingly that particular anesthetic agent either isoflurane 
or sevoflurane was used throughout the procedure. 
 
Pre-op evaluation 
Following a thorough preoperative check up the procedure was 
explained to the patient.  After obtaining informed consent, patients are 
randomly allocated to one of the two groups. 
Antiplatelet therapies were stopped 1wk before the operation and 
replaced by Heparin.  ACE inhibitors are stopped one day prior to the surgery 
as a routine in our institution. Oral anti diabetic drugs were continued upto the 
night prior to surgery. Beta blockers and nitrates were continued upto the 
morning of surgery. 
Patients were premedicated with benzodiazepines and opioids one 
hour prior to the procedure.   
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Monitors: Equipment used for monitoring the patient during the surgery 
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MONITORING  
In the operating  room  patients received routine monitoring, including 
leads II and V on the electrocardiogram, O2 saturation by pulse oximetry, 
capnography, continuous  radial arterial and central venous pressure and 
temperature monitoring which included nasopharyngeal ,rectal and blood. The 
hemodynamic measurements performed for intermittent cardiac output 
monitoring by thermo dilution method includes mean pulmonary artery wedge 
pressure (PCWP), systolic diastolic and mean systemic arterial pressure 
(SAP), systolic, diastolic and mean pulmonary arterial pressure (MPAP), mean 
right atrial pressure (RAP) and heart rate. Derived hemodynamic values of 
cardiac output, cardiac index (CI) and systemic vascular resistance (SVR) at 
induction were recorded. The Bi spectral index (BIS) monitor was attached to 
the patient and maintained at 40 – 60 throughout the surgery and during 
cardiopulmonary bypass. 
 
Induction 
After securing I.V. access, radial arterial blood pressure and other 
monitors like pulse oximetry (Spo2), electro cardiogram (ECG) were 
established. Before inducing the patient, a blood sample was taken for 
biochemical tests (Sample A). Patients were induced with midazolam (5mg), 
fentanyl (5-10mcs\kg), air oxygen and isoflurane (group A) or sevoflurane 
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(group B). When they were asleep, muscle relaxants (vecuronium or 
pancuronium or combination) was given. After intubation internal jugular vein 
on the right side of the neck was cannulated. 
 
Pulmonary arterial catheter insertion 
In all patients, a 7.5Fr Swan Ganz catheter was introduced through an 
8.5Fr introducer sheath, sited in the right internal jugular vein. The distal lumen 
of the Swan Ganz catheter is connected to a pressure transducer to record the 
pressure waves continuously. Once the tip of the catheter reached the right 
atrium, as indicated by the pressure waveform, the balloon was inflated with 
1.5ml of air and the catheter was gently floated through the right ventricle(RV) 
and finally into the pulmonary artery (PA). The catheter was guided till the tip 
was wedged in one of its branches as indicated by a PA wedge pressure 
tracing. At this position, if the balloon is deflated, the pulmonary artery 
pressure waveform should be seen. All the pressures were measured with the 
transducer kept at the level of the mid-axillary line. The cardiac output catheter 
has a thermistor at the tip which measures blood temperature continuously. 
Cardiac output is measured intermittently by injecting 10 ml cold saline in the 
CVP lumen (right atrial), the change in temperature was measured at the tip of 
the catheter from which the cardiac output was calculated. 
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Maintenance 
Stress responses were tackled with incremental doses of fentanyl and 
isoflurane or sevoflurane according to the groups they were allocated.  After 
going on pump, Isoflurane or Sevoflurane was administered via a special 
vaporizer attached to the pump maintaining the BIS around 40-60. During 
rewarming, muscle relaxants and opioids were given. 
Two blood samples, one 60 minutes after aortic cross clamp 
release(Sample B) and the second (Sample C) 60 minutes after separation of 
pump are taken for biochemical analysis.  After separation from the 
Cardiopulmonary bypass (CPB) pump, anesthesia is maintained with opioids, 
air, oxygen and isoflurane or sevoflurane according to the allotted group. 
 
Surgical aspect 
Median sternotomy and pericardiotomy were performed. After 
administration of 3mg/kg unfractionated heparin, the aortic cannula was 
secured in place. Activated coagulation time (ACT) was kept at 450secs or 
three times above the baseline ACT value throughout the cardiopulmonary 
bypass (CPB). Routine surgical techniques and cardio protective strategies 
were used in both groups. Cardiac protection was obtained with cold 
cardioplegic solution. Body temperature was cooled to 30°C-32°C on CPB. 
After the surgical procedure, the heart was reperfused and rewarmed to a 
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rectal temperature of 35°C-36°C. Inotropes mainly used was adrenaline in a 
dose of less than 0.1µg/kg/hr. This was started in both groups before 
separation from cardiopulmonary bypass and continued throughout post pump 
period and in the intensive care unit (ICU) depending upon the hemodynamic 
parameters of the patient. After neutralizing the heparin activity with 
protamine, the aortic cannula was removed. Protamine administration was 
further guided by activated coagulation time measurements aiming for a value 
of below baseline ACT. At the end of the procedure, patients were transferred 
to ICU, where they were kept sedated with morphine and midazolam. The 
patients were then weaned from the ventilator and tracheally extubated. 
All patients included in this study were operated by a single surgeon in 
order to standardize the techniques, the duration of CPB and surgery. This is 
because duration of ischemia can influence Ischemic reperfusion injury (IRI). 
 
Measurement of Cardiac output during surgery 
Three pre-bypass measurements of cardiac output and cardiac indices 
were measured and the average was taken. Post-bypass, three 
measurements were taken and the averages of those were also taken. 
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Measurement of O2 free radicals and CK-MB 
Blood samples were sent to biochemical lab for measurement of 
biochemical markers of oxidative stress during CABG. We estimated 
malondialdehyde as a marker of lipid peroxidation, protein carbonyl content as 
an indicator of protein oxidation, protein thiols and total thiols to evaluate thiol 
status and nitrate (the stable end product of nitric oxide) to evaluate nitrosative 
stress. We took 3 blood samples at different time points; sample A at pre 
induction, sample B one hour after cross clamp release and sample C one 
hour after separation from pump. Oxidative stress was expected to increase 
after reperfusion phase but this could not be measured as the presence of 
some anesthetic agent was required on pump due to ethical considerations. It 
was hoped that the samples collected before induction could be used as 
baseline and compared against the other time points where volatile anesthetic 
agent would be present.  Measurement of protein carbonyls, malondialdehyde, 
nitrates, protein thiols and total thiols were done for each of these samples. 
The actual method of determining these are given in the appendix. 
 Initially a pilot study was done on five patients to decide which cardiac 
biochemical marker would be the best indicator of post CABG myocardial 
ischemia. Creatinine Kinase – MB (CK-MB) was seen to rise within 4 to 8 hrs 
and peak at 12hrs, while Troponin-I levels remained elevated for 72 hours. 
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From our pilot study we concluded that plasma CK-MB levels would be a 
better indicator for postoperative MI because of its rapid rise and fall than 
troponin I values. Blood samples were taken from all patients for determination 
of creatinine kinase-MB (CK-MB). These samples were obtained at arrival in 
the ICU (T0) and at 12hrs (T12) after arrival in the ICU.  
Sample size 
The sample size was calculated with the following formula based on a 
previous study by Cason, Brian A et al (46).  
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For a power of 90% and α = 5%, a sample size of 6 patients in each group 
was calculated to be appropriate. 
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Statistical analysis 
Patient characteristics, hemodynamics parameters and biochemical 
markers were compared using non parametric Mann-Whitney, Wilcoxon 
signed rank test, paired t test and Fisher’s exact test wherever appropriate.  
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RESULTS 
 
20 patients scheduled for coronary artery bypass grafting on CPB were 
enrolled in the study. Two patients were not included in the analysis; one 
surgery was done off pump, hence excluded from the analysis. In the other 
patient, due to damage of coronary sinus during surgical manipulation there 
were problems of separation from CPB pump, the patient required an Intra 
aortic balloon pump (IABP) as well as a pacemaker for weaning from bypass.  
 
Table 1 shows the demographic data of patients in both  groups. There 
were no significant differences in age, weight, height and gender of the 
patients between the two groups. As can be seen from this table, there was 
only one female included in the study. 
 
 
Table 2 describes the premorbidity status of all patients. There was no 
statistically significant differences between the two groups .One patient in 
Group 2 had aortic stenosis and another had four vessel disease. 
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Table 1-Demographic data 
 Group 1(n=9) Group 2(n=9) 
Age(mean+/_SD) 55.67 ± 9.42 52.56 ± 7.98 
Height(cms) 166.78 ± 6.8 163.11 ± 7.47 
Weight(kg) 57.67 ± 7.890 65.89 ± 12.150 
Sex(male: female)    8 : 1      9 : 0 
Table 2 – Pre-operative morbidity 
Morbidity factors Group1(n=9) Group2(n=9)
 
NYHA 
CLASS 
I           0            0 
II           6            7 
III           3                  2 
IV           0                   0 
LV dysfunction (angio)           2            4 
     Hypertension           5            5 
      Diabetes mellitus           2            4 
Diseased 
vessel 
Double           2            2 
Triple           7            6 
Four           0             1 
Associated MR(functional)           1               2 
Hypothyroidism           1            1 
AS           0            1 
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Cardiac output (CO) (L/min) 
The mean pre pump CO was 5.18 and 5.1L/min in Group 1 and Group 
2 respectively. Likewise the mean post pump CO was 8.9 and 8.11L/min 
respectively.  
There was no significant statistical difference between the 2 groups 
Cardiac index (L/min/m²) 
The mean pre pump CI was 3.12 and 2.84L/min/m² in Group 1 and 
Group 2 respectively. Likewise the mean post CPB CI was 5.32 and 
5.01L/min/m² respectively. Here also we found no statistical difference 
between both groups. 
Systemic vascular resistance (SVR) (dynes. sec. cm-5) 
The SVR value in Group 1 was not statistically different when compared 
with Group 2 during pre and post CPB period. It was observed that in the  post 
CPB period, there was fall in systemic vascular resistance in both Groups. 
Other hemodynamic parameters were similar in both groups. 
Table 4 gives the duration of CPB and ICU stay in both the groups. The 
CPB duration was more than 2hrs in 4 patients, 2 in isoflurane group and 2 in 
sevoflurane group. There was no difference in CPB duration between both the 
groups. 
ICU stay exceeded 24 hrs in three patients, 2 in the isoflurane and 1 in 
sevoflurane group. But none of them stayed beyond 36 hrs in ICU. 
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Table 3 
Haemodynamics with Isoflurane and Sevoflurane - Mean ±- SD 
 
 
 
 
 
Table -4 CPB duration and ICU stay 
 Group 1 Group 2 
CPB DN (hrs) 1.5 ± 0.02 2 ± 0.02 
ICU stay (hrs) 21.7 ± 6.86 19 ± 2.52 
 
 Basal Pre-CPB Post-CPB 
HR (bpm) 
Isoflurane 
Sevoflurane 
 
68.66 ± 8.12 
80.8 ± 22.6 
 
75.66 ± 8.12 
79.66 ± 12.3 
 
87.33 ± 8.29 
89.33 ± 9.96 
MAP(mmhg) 
Isoflurane 
Sevoflurane 
 
87.77 ± 7.57 
90.33 ± 7.85 
 
74.11 ± 8.90 
74.77 ± 8.01 
 
75.77 ± 8.12 
73.33 ± 8.07 
CVP(mmhg) 
Isoflurane 
Sevoflurane 
 
6.55 ± 2.78 
6.22 ± 2.68 
 
7 ± 2.06 
7.8 ± 2.36 
 
8.11 ± 1.16 
6.88 ± 1.76 
CO(L/min) 
Isoflurane 
Sevoflurane 
 
____ 
____ 
 
5.18 ± 1.13 
5.10 ± 0.98 
 
8.90 ± 1.70 
8.11 ± 1.26 
CI(L/min/m²) 
Isoflurane 
Sevoflurane 
 
_____ 
      _____ 
 
3.12 ± 0.61 
2.84 ± 0.68 
 
5.32 ± 0.89 
5.01 ± 0.73 
SVR(dynes.sec/cm5)
Isoflurane 
Sevoflurane 
 
_____ 
_____ 
 
1087 ± 251 
980 ± 178 
 
602 ± 155 
677 ± 134 
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OXIDATIVE STRESS BIOCHEMICAL MARKERS 
 
 
 
Protein Thiols 
 
Figs 3.shows in the isoflurane group, protein thiol levels were not 
reduced at time B but at time period C, levels were reduced. In the sevo 
group, thiol levels were reduced both at time period B and C. But there was no 
statistically significant difference in the fall of thiol levels between the 2 groups 
(P>0.05) 
 
 
 
Fig 4, 5, 6 and 7 shows the distribution pattern of protein thiol levels in 
B and C samples for the iso and sevo groups. 
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Total Thiols 
 
       In the isoflurane group the total thiol level were increased from the 
baseline value at time B, but was reduced below the baseline value at time C 
(fig 8.). In the sevoflurane group, total thiols were reduced below the baseline 
at time B, but increased and reached the baseline values at time C. There was 
no statistically significant difference between these two groups (P> 0.05). 
 
  Fig 9, 10 ,11 and 12 shows the distribution pattern of total thiols in B 
and C samples for the iso and sevo groups. 
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Malondialdehyde 
 
Fig 13 shows malondialdehyde levels in the isoflurane group were 
decreased from baseline at time C, but there was no fall at time B. In the 
sevoflurane group though malondialdehyde levels reduced at time B and also 
at time C. This change in levels had statistical significance at time point C           
(P= 0.02). 
 
 
 
We can see the distribution pattern for malondialdehyde levels in fig 14, 
15, 16 and 17 for both iso and sevo groups. 
 
  51
 
 
 
 
 
 
 
        Fig 13.Levels of Malondialdehyde 
nmoles / ml
2.252.001.751.501.251.00.75.50
Fig 15. Mal Level - Sevo group
Sample B
no
 o
f p
at
ie
nt
s
2.5
2.0
1.5
1.0
.5
0.0
Std. Dev = .59  
Mean = 1.03
N = 9.00
nmoles / ml
2.502.001.501.00.500.00
Fig 16.Mal Level - Iso group
Sample C
no
 o
f p
at
ie
nt
s
3.5
3.0
2.5
2.0
1.5
1.0
.5
0.0
Std. Dev = .76  
Mean = 1.10
N = 9.00
nmoles / ml
1.501.251.00.75.50.25
Fig 17.Mal Level - Sevo group
Sample C
no
 o
f p
at
ie
nt
s
5
4
3
2
1
0
Std. Dev = .42
Mean = .73
N = 9.00
0
0.5
1
1.5
2
2.5
Before induction 1 hour after cross
clamp
1 hour after coming off
pump
Isoflurane Sevoflurane
Malondialdehyde
nm
ol
es
/m
l
nmoles / ml
5.04.03.02.01.00.0
Fig 14.Mal level - Iso group
Sample B
no
 o
f p
at
ie
nt
s
5
4
3
2
1
0
Std. Dev = 1.39  
Mean = 1.3
N = 9.00
  52
 
Protein Carbonyls 
 
In the isoflurane group, protein carbonyl levels were reduced from the 
baseline value at time B, and the same level maintained at time C. In the 
sevoflurane group, though there was a decline in protein carbonyl level at time 
B, there was a mild increase at time C but did not reach the baseline values. 
This difference was also not statistically significant between the 2 groups 
(P>0.05). 
 
 
Fig 19 to 22 displays the distribution pattern of protein carbonyl levels 
for both iso and sevo groups at time period B and C. 
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                      Nitrosative Stress Bio chemical marker 
 
 
 
 
 
Nitrates   
From fig 23 it can be seen that in the iso group there was no significant 
decrease in nitrate levels at time B and C. But there was significant decline in 
nitrate level at time B and C in the sevo group. This was shown to be 
statistically significant (P= 0.03).  
 
 
   Fig 24 to 27 shows the distribution pattern of nitrate levels in both the 
groups at time period B and C. 
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CARDIAC BIOCHEMICAL MARKERS 
Table 5 shows the Creatinine Kinase MB (CK-MB) for both isoflurane 
and sevoflurane at 0 hr and 12 hrs after admitting into ICU. From fig 28 it is 
evident that CK-MB values were decreasing at 12 hrs in sevoflurane group. 
But this difference did not attain any statistical significance. 
Table 5. Post operative CK-MB values 
   Group 1 (n=9) Group 2 (n=9) 
CK-MB (T0) [U/L] 23.11 ± 5.2 29.89 ± 15.46 
CK-MB (T12) [U/L] 23.44 ± 5.02 25.44 ± 19.6 
          
Fig 28. Representation of postoperative CK-MB values   
 
0
5
10
15
20
25
30
35
40
45
50
1 2
Isoflurane
Sevoflurane
  57
                                        DISCUSSION 
Coronary Artery Bypass Graft (CABG) surgery is still considered the 
best treatment for Myocardial Ischaemia (MI), but it has been reported that 
90% of patients undergoing CABG surgery have a fall in ejection fraction and 
cardiac index during the immediate post-operative period even with 
cardioplegic protection and hypothermia widely practiced all over the world. 
This has been attributed to various factors including ischemia associated with 
aortic cross clamping, inadequate myocardial protection and the consequent 
ischaemic reperfusion injury (IRI) during surgery. In recent years it has been 
shown that myocardial ischemic preconditioning has been accepted as one of 
the interventions for myocardial preservation. More recently, studies have 
shown that myocardial preconditioning can be achieved with propofol, opiates 
and various volatile agents like halothane, enflurane, isoflurane, sevoflurane 
and desflurane.  
Volatile agents have definitely been proven to be more effective than 
propofol or opiates (69). Only few studies have evaluated differences in 
preconditioning effects between the different volatile agents in human 
myocardium. Many animal studies have shown that isoflurane is better than 
halothane, enflurane and propofol in achieving cardiac protection and causing 
lesser ischaemic episodes in the postoperative period. Recent animal studies 
have suggested that sevoflurane may confer better cardiac protection. But 
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there are hardly any studies comparing isoflurane with sevoflurane. Hence we 
decided to compare these two agents to determine whether their continuous 
administration in patients undergoing CABG surgery will provide adequate 
cardiac protection. Earlier studies have shown that discontinuation of 
anesthetic agent more than 30min before occlusion of the coronary artery 
resulted in loss of the preconditioning effect (70). Hence we decided to use the 
volatile agents pre-pump, throughout CPB and also post pump to achieve both 
early (lasting between 1 to 3 hours) and late (lasting for upto 72 hours) pre-
conditioning effects. 
Generation of reactive oxygen species (ROS) is central to reperfusion 
injury and this is responsible for cellular toxicity and activation of 
proinflammatory cells such as neutrophils and mast cells. Oxygen free radical 
production can result in damage to a variety of cellular components resulting in 
peroxidation of lipids, oxidation of proteins and loss of cellular thiols. To 
evaluate the effect of sevoflurane and isoflurane on oxidative stress during 
CABG, we estimated malondialdehyde as a marker of lipid peroxidation, 
protein carbonyl content as an indicator of protein oxidation, protein thiols and 
total thiols to evaluate thiol status and nitrate (the stable end product of nitric 
oxide) to evaluate nitrosative stress.  
Plasma levels of matrix metalloproteinase (MMP-9), a biochemical 
marker of neutrophil activation and brain natriuretic peptide (BNP), a marker of 
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myocardial dysfunction are increased during oxidative stress reactions.  
Volatile agents especially sevoflurane have shown to reduce the activation of 
neutrophils and reduce the BNP levels. Hence determination of these levels 
would probably give us the exact degree of oxidative stress. Unfortunately the 
facilities required to measure these parameters were unavailable in our 
institution and so we did not measure those values. 
Initially a pilot study was done on five patients to decide which cardiac 
biochemical marker would be the best indicator of post CABG myocardial 
ischemia.  In this study CK-MB values had declined by 12 hours post surgery 
while but troponin I values remained high. So we concluded that plasma CK-
MB levels would be a better indicator for postoperative MI because of its rapid 
rise and fall than troponin I values. Normal CK-MB values in our institution are 
less than 24u/l and three times this value is taken as significant for ischemia 
along with ECG changes for ischemia. 
All the CK-MB values decreased after 12 hours. (29.89 in iso vs 25.44 
in the sevo) .The values were found to be lower in the sevoflurane group after 
12 hrs though this did not reach statistical significance. There was no 
significant difference in morbidity in both the groups. There were no new 
ischemic changes or hemodynamic instability noticed in any of the patients in 
the immediate postoperative period or during their ICU stay except one patient 
who to be re explored for a surgical bleed. 
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According to our data, the hemodynamic parameters obtained with use 
of isoflurane and sevoflurane groups were comparable, with hardly any 
difference in cardiac index (CI) and systemic vascular resistance (SVR). 
A sharp decline in SVR and large increase in CI was seen in all patients 
immediate postop, probably due to use of GTN and the volatile agent, both 
being vasodilators. (CI of 5.32 ± 0.89, SVR of 602 ± 155in isoflurane group 
during immediate post bypass compared with CI of 5.01 ± 0.73, SVR of 677 ± 
134 in sevoflurane group).         
This indicates that isoflurane and sevoflurane have similar cardiac 
effects in the immediate postoperative period. Kersten et al have 
demonstrated that sevoflurane selectively increased collateral flow to ischemic 
areas in the dogs with chronic LAD stenosis (69) and can maintain the 
vasodilating effect of independent vasodilators. 
Intensive care unit (ICU) stay and discharge was also similar in both 
groups and no advantage of one group over the other was evident. This was 
also shown by  De Hert and colleagues (71)  who have shown that there is 
significant decrease in ICU and hospital length of stay in the volatile groups 
(sevoflurane and desflurane) when compared with the non-volatile agents 
(propofol and midazolam).  
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For evaluation of oxidative and nitrosative stress, 3 blood samples were 
taken at different time points; sample A at pre induction, sample B one hour 
after cross clamp release and sample C one hour after coming off bypass. 
Parameters of oxidative and nitrosative stress such as protein thiols, total 
thiols, protein carbonyls, malondialdehyde and nitrates were measured in each 
sample. Based on the literature, it was expected that oxidative stress would 
increase during the reperfusion phase, but this could not be measured in this 
study since an anaesthetic agent had to be present during CPB due to ethical 
considerations. It was hoped that the sample collected before induction could 
be used as a baseline, and compared against the other time points, where 
anaesthetic would be present.  
Thiols are necessary for normal cellular function and also constitute 
important anti-oxidant defenses in cells. Thiol groups on proteins also have 
critical roles in protein function and are also susceptible to damage by ROS. 
Oxidative stress would result in a decrease in total thiol content, which may be 
accompanied by decreases in protein thiols if thiol groups on proteins are 
damaged.  
As per our study change in serum total thiols during CABG surgery 
shows that patients in the isoflurane group had an increase in total thiols after 
initiation of ischemia by cross clamping. This could be due to a decrease in 
constitutive levels of free radicals because of a lack of oxygen, resulting in 
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sparing of thiol anti-oxidants. However after subsequent reperfusion (point C) 
thiol levels show a sharp decrease, which is expected since reperfusion would 
result in a significant increase in ROS production. It is interesting to note that 
the response with sevoflurane is different from that for isoflurane. Here serum 
total thiol shows a slight decrease during ischemia and then does not change 
during reperfusion, in fact showing a slight increase. This indicates that 
presence of sevoflurane is able to spare thiols during reperfusion, and has a 
beneficial effect during later stages. It should be noted however, that if neither 
isoflurane nor sevoflurane were used in pump, the changes in thiols probably 
would have been more dramatic.  
Looking at protein thiols, our data shows that serum levels of protein 
thiols are decreased in both pre and post CPB period with both agents when 
compared to the initial baseline values. This indicates that oxidative stress 
during CABG did affect thiol groups on proteins. According to the data, fall in 
thiol levels were more with sevoflurane when compared with isoflurane, but 
this difference did not attain statistically significant value probably due to the 
small sample size.  
Lipid peroxidation is another important indicator of damage during 
oxidative stress, and malondialdehyde is one of the main products of lipid 
peroxidation. An increase in levels of malondialdehyde in serum would thus be 
indicative of oxidative stress. According to our study, the levels of 
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malondialdehyde in serum from patients at different time points during CABG 
shows presence of sevoflurane results in a decrease in malondialdehyde 
levels suggestive of protection against oxidative stress. This was not evident in 
the isoflurane group, which did not change. After bypass, during the 
reperfusion phase, presence of isoflurane prevented any increase in 
malondialdehyde, suggesting protection against lipid peroxidation. The effect 
of sevoflurane during this phase is more dramatic, since the decrease in 
malondialdehyde levels initiated in the ischemic phase is sustained. This 
indicates that presence of sevoflurane provides better protection against lipid 
peroxidation both during pre as well as post bypass periods when compared to 
isoflurane. This is statistically significant (P = 0.02). Again it should be noted 
that presence of isoflurane prevented the expected increase in 
malondialdehyde during reperfusion, an effect which could not be 
demonstrated in this study due to absence of the control group due to ethical 
reasons.  
 
Proteins are important targets of oxidative stress, and protein carbonyl 
content is a marker of protein oxidation. Oxidative stress in serum would thus 
result in an increase in protein carbonyl content. Our study shows that the 
levels of serum protein carbonyls is decreased in both isoflurane and 
sevoflurane treated groups. As can be seen, during the ischemic pre bypass 
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period patients in both groups show a decrease in protein carbonyl content. In 
the post bypass period during reperfusion, levels do not change very much, 
though the sevoflurane group does show a slight increase. All the above data 
indicates that protein carbonyl content is similar between the groups at the 
later time points B & C. This implies that presence of either anesthetic in pump 
during CABG prevents protein oxidation, and has a beneficial effect.  
Nitric oxide (NO) is now recognized as an important signaling molecule 
and high levels of NO can have damaging effects. Interaction of NO and ROS 
such as superoxide can result in production of nitrosative species such as 
peroxynitrite, which can damage cellular components. Nitric oxide is rapidly 
metabolized to stable end products such as nitrate, and this was measured in 
serum from patients undergoing CABG as an indicator of nitrosative stress. 
High levels of nitrate reflect increased NO levels and are generally damaging. 
Our data shows that there was no increase in nitrate levels after ischemia, or 
after reperfusion, suggesting that anaesthetic preconditioning had a protective 
effect. The levels were lower in patients treated with sevoflurane when 
compared to the isoflurane group at both early reperfusion and immediate post 
bypass period when the oxidative stress is greatest. This suggests that 
sevoflurane provides better protection than isoflurane during these phases of 
CABG.  This difference in levels between the two groups attained statistical 
significance (P=0.03) for the two later time points. However the use of Glyceryl 
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trinitrate (GTN) throughout the surgery would have been affected the levels of 
nitric oxide in plasma levels and hence it is difficult to come to a conclusion. 
Paradoxically however, reactive oxygen species have also been 
implicated in the mechanism of anaesthetic preconditioning, which is cardio 
protective. It has been suggested that anaesthetic pre-conditioning increases 
generation of reactive oxygen species, mediated by a partial inhibition of 
mitochondrial respiration. One explanation for these opposing effects could be 
the relative concentrations of free radicals generated in ischemia reperfusion, 
versus pre-conditioning. Even though all the above data imply that there is 
oxidative stress involved during cardiopulmonary bypass, thiol levels probably 
might have been much lower and the levels of malondialdehyde, protein 
carbonyls and nitrates might have been much higher if we had not used either 
of these agents during CPB period. Since similar doses of narcotics, 
benzodiazepines, cardioplegia and hypothermia were used in all the patients 
in both the groups, potentiation of cardio protective effects with these should 
also be similar. Concentrations of volatile agents used in all the previous 
studies for cardioprotection have been in the ranges between 0.5 – 2 MAC 
which is relevant to clinical practice. In our study also we were able to achieve 
these cardiac effects within these concentrations of isoflurane and 
sevoflurane, though we actually used Bispectral Index (BIS) monitoring to 
maintain a value around 40-60 for adequate depth of anaesthesia. 
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In conclusion, our data in this study indicate that preconditioning with 
volatile anaesthetics such as isoflurane or sevoflurane definitely has beneficial 
effects in preventing oxidative stress during CABG. Among the two agents, 
isoflurane seems to provide better protection during the pre-bypass and early 
reperfusion period, while sevoflurane provides protection not only during early 
reperfusion but also in the immediate post operative period. 
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Limitations of our study 
            
 1)  Current practice in most of the centres in India is not to use volatile 
agents during CPB, instead depending on high dose narcotics for 
analgesia, awareness and cardioprotection. Though we wanted to 
include this protocol for our control group, it was not approved by the 
Institutional Ethics Committee and hence we compared only these 2 
groups (isoflurane and sevoflurane) for the study. 
2)   All the CABG patients are routinely on Glyceryl trinitrate (GTN) 
throughout the surgery, which leads to a loss of systemic vascular 
resistance (SVR) and increased cardiac index (CI) at the end of surgery 
and immediate post-operative period. We were not able to measure CI 
and SVR in the ICU post operatively. A normal SVR would have 
accurately reflected the true CI. Also the nitrate values obtained might 
have been influenced by GTN. 
3)  As a rule, in our hospital post CABG patients are ventilated in ICU 
overnight and weaned the next day morning. They are discharged from 
ICU after 24 hours, one day ICU stay was mandatory for all patients, so 
we were unable to compare ICU stay and early discharge between the 
2 groups. Also long term morbidity between the two groups was not 
assessed. 
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4)  Reactive oxygen species (ROS) have been implicated to have a 
significant role in preconditioning. Initial low concentrations of ROS 
have been shown to be protective, an effect which could not be 
demonstrated in this study due to absence of the control group due to 
ethical reasons. This could be the reason for some of the opposing 
effects seen before and after bypass. 
5)  We had only one female patient in the whole study, so we were not able 
to come to any gender based conclusions. 
6)  The cost of the study included the cost of a PA catheter, sophisticated 
monitoring equipment for pulmonary artery pressure, cardiac index 
measurements and estimation of the biochemical markers. The cost 
involved for all of the above is quite high for a developing country like 
India. To do a study with a larger sample size would require a lot of 
funds, hence this can only be taken as a pilot study.   
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                                   CONCLUSIONS 
1) Our study strongly indicates definite cardiac preconditioning effects with 
both the volatile agents isoflurane and sevoflurane in clinically relevant 
concentrations when administered throughout CABG surgery.  
2) The evidence of oxidative stress with CABG surgery was shown by 
decreasing levels of biochemical markers. The preconditioning effects 
with these agents were evident from the ease of separation from CPB 
bypass and outcome of surgery in the immediate post-operative period 
as shown by the clinical and biochemical markers at different time 
intervals. 
3) Among the two agents, isoflurane seems to provide better protection 
during the pre-bypass period and early reperfusion, while sevoflurane 
provides protection during early reperfusion as well as immediate post-
bypass period when the oxidative stress is much greater. 
 
 Taking into account patient variability and the different mechanisms 
involved with different anaesthetic agents, larger adequately powered trials 
with defined outcomes need to be done to fully assess a possible beneficial 
effect of one volatile anaesthetic agent over the other and arrive at definite 
conclusions.   
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APPENDIX 
       
    Pre-operative Data 
 Hypertension (Duration and Treatment) 
 
 Diabetes mellitus (duration and treatment) 
 
 Renal dysfunction (Serum creatinine value) 
 
 COPD\Asthma (specify PFT report) 
 
 Any other medical illness –Specify 
 
 Number of diseased vessels & Any cardiac 
dysfunction 
 
 Any other cardiac illness(valvular,congenital) 
 
 Preoperative medications (antiplatelet & others) 
 
     
 Intra-operative data – 
                                                                       
PROFORMA 
 
Comparison of cardiac preconditioning effects of isoflurane and sevoflurane 
in coronary artery   bypass graft surgeries done on Cardio Pulmonary 
Bypass 
     
   Hosp.no:                                                              Serial no:   
 
   Name:                                                                  Age:              Sex:        
 
   Weight:                    Height:                                 Date: 
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                                    Baseline                        Prepump               
Post pump 
              Heart rate 
             Arterial Bp 
             Saturation 
             CVP 
              
BIS (Average)                            Prepump 
                                                   Intrapump    
                                                   Postpump  
 
                                                 
                                      Prepump                                      
Postpump 
                                          
Cardiac output 
 
Cardiac index 
 
SVR 
 
 
Biochemical parameters (samples to be taken from radial arterial 
line) 
 
 Sample A-Before induction 
 Sample B-One hour after Aortic 
cross clamp    
                   release      
 Sample C-One hour after coming 
off bypass 
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Duration of CPB            : 
 
 
 
Post-operative data 
 
       Biochemical marker 
 Creatinine kinase MB (0hr and 12 
hrs later) 
 
 
       Duration of ICU stay 
 
       Any other problems in (ICU specify in detail) 
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                                INFORMATION TO THE PATIENT AND CONSENT 
FORM 
 
Introduction 
 
Hello, my name is Dr. Sathish Kumar D. and I am working in the 
department of Anesthesiology CMC Hospital Vellore.  We are conducting a 
study that can help to influence cardiac function and postoperative benefits 
like reduced ICU stay.  First, the procedure is done only in the presence of 
senior supervision inside the operation theatre with all the usual monitoring 
required for the surgery done in our centre.  
 
Study procedure 
                           As you know, CABG is done in the operation theatre.  After 
taking you inside the operation theatre an intravenous line will be started.  
After establishing monitors, you will be asked to take a good breath through 
mask with oxygen.  Depending on the randomization, you will be administered 
general anaesthesia using a gaseous agent (either Isoflurane or Sevoflurane).  
Your vitals will be monitored intraoperatively using standard monitoring.  
Biochemical tests for cardiac function will be sent during the procedure and 
also during the postoperative period in the ICU.  At the end of the procedure 
you will be taken to the ICU without waking up, where you will be ventilated for 
a day with all the usual monitoring.  Then you will regain consciousness and 
the endotracheal tube will be removed.  
 
Benefits 
               By this study, we hope your cardiac function after surgery will 
become better.  Further ICU stay and postoperative hospital stay will be 
shorter.  You will be comfortable and asleep during the intra op and post op 
period.  You will have adequate pain relief during the procedure.   
 
Discomfort and risks 
              It will be the same like any other general anaesthesia for cardiac 
surgery.  Additional blood tests and monitoring which are done to look for 
improvement in cardiac function will not cause any discomfort as you will be 
asleep then. 
 
Confidentiality 
              Your name will not appear on the study records.  Information related 
to you will be marked in a code sheet and only the study doctor will be able to 
link your name with the code number.  
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Participation in the study 
               Your participation in this study is entirely voluntary and you have the 
right to refuse to volunteer for this study.  Your care will not be affected by this 
decision.  However if you volunteer, you are required to sign or put your thumb 
print on the following consent form. 
 
 
CONSENT 
 
         I have read this consent form and have discussed the procedure with Dr. 
D. Sathish Kumar.  The details of this study have been explained to me.  I 
have been given the opportunity to ask questions, which have been answered 
to my satisfaction.  I understand that this study is voluntary.  I understand that I 
can refuse to participate in the study and my care will not be affected by this 
study.  I give my consent to be enrolled in this study. 
 
 
 
 
 
Signature of the participant                                       Signature of the 
Anaesthetist 
 
 
 
Name of the patient: 
 
Hospital No: 
 
Date: 
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Measurement of protein carbonyls, protein thiols and total thiols 
Blood samples are treated with 10ml 2-4 dinitrophenyl hydrazine dissolved in 
2N hydro chloric acid(HCl) followed by incubation at room temperature for 1 hour. 
Trichloroacetic acid (10% final concentration) will then be added, followed by 
centrifugation to pellet the precipitated protein. To this pellet an equal volume of 1:1 
(v/v) ethyl acetate: ethanol are added. Following centrifugation, the pellet is collected 
and dissolved in 1ml of 6M guanidine HCl. Absorbance at 366nm is then measured, 
and expressed as nmoles/mg protein. Total thiol content was measured using DTNB 
[dithio-bis-2-nitrobenzoic acid] and expressed as nmoles/mg protein. 
Measurement of malondialdehyde 
For measurement of malondialdehyde, serum samples was treated with 
200microlitre of 8.1%SDS, 1.5ml of 20% glacial acetic acid pH 3.5 and 1.5ml of 0.8% 
thiobarbituric acid. The samples are incubated at 100°C for 1 hour. The absorbance is 
then read at 532nm and amount of malondialdehyde formed is calculated from a 
standard curve prepared using 1, 19,3,39 tetramethoxypropane and expressed as 
nmol/mg protein. 
Estimation of serum nitrate levels 
Estimation of nitrate and nitrite, the stable end products of nitric oxide 
oxidation, is a common indirect method to monitor NO levels. Nitrate in the samples 
must first be reduced to nitrite, which is then measured by the Griess reaction. 
Reduction of nitrate to nitrite will be carried out using a copper-cadmium alloy. Copper 
cadmium alloy is prepared by mixing molten copper with cadmium in the ratio 1:9. 
Filings of the alloy are then prepared, followed by activation as follows- The copper-
cadmium alloy filings are washed twice with 100ml of de-ionized water, followed by 
two washed with 0.5N HCl. The activated filings are then washed with 0.1N HCl and 
stored in 0.1N HCl at 2-8oC until use. For analysis of nitrate/nitrite, samples were 
incubated with the alloy filings in carbonate buffer for 1 hour at room temperature with 
shaking. The reaction is stopped by addition of 0.35M NaOH and 120mM ZnSO4 
solution, followed by vortexing. After standing for 10 minutes, the samples are 
centrifuged at 4000g for 10 minutes. Aliquots of the clear supernatant are treated with 
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1% sulfanilamide and 0.1% N-naphthylethylenediamine. After 10 minutes, the optical 
density is read at 545nm in a spectrophotometer. 
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1 
2 
3 
4 
5 
6 
7 
 
8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                 
S NO 
HOS NO 
AGE  
WT 
HT 
WT 
NYHA class 
 
PREOP DATA 
  Bp 
 
  DM 
 
  rendys 
 
 
  copd 
 
  ves_blk 
 
  sys dysfn 
 
 
  Ef 
  Others 
   MR-fnal 
 
   hypothy 
 
  AS-cal 
  hr-base 
  hr- pre 
 
 hr-post 
 
 map-pre 
 map- pre 
 map-post 
 
 SPO2 
 cvp-base 
 
 cvp-pre 
 cvp-post 
                                                            
Serial number 
Hospital number 
Age 
Weight 
Height 
Weight 
New york Heart association 
Classification 
Preoperative morbidity 
Hypertension 
 
Diabetes mellitus 
 
Renal Dysfnction 
 
 
Chronic obstructive pulmonary 
disease 
Number of coronary vessels blocked 
 
Systolic dysfunction-Angiogram 
finding 
 
Ejection fraction 
Other preoperative problems 
Functional Mitral regurgitation 
 
Hypothyroidism 
 
Calcific aortic stenosis 
Baseline heart rate 
Heart rate prior to cardiopulmonary 
bypass (CPB) 
Heart rate after CPB 
 
Baseline mean arterial pressure 
Mean arterial pressure prior to CPB 
Mean arterial pressure after CPB 
 
Baseline oxygen saturation 
Baseline central venous pressure 
(CVP) 
CVP prior to CPB 
CVP after CPB 
 
 
 
 
 
 
 
 
 
 
0-no hypertension 
1 - hypertension 
0 – non diabetic 
1 - Diabetic 
0 – No dys function 
1 – dysfunction 
present 
0 – no copd 
1 - copd 
 
 
0 – sys dys absent 
1 – sys dys present 
 
 
0 – No problems 
1 – Functional mitral 
regurgitation 
2 – Hypothyroidism 
3 – calcific aortic 
stenosis 
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10 
 
 
 
 
11 
 
 
 
12 
 
 
 
13 
 
 
 
14 
15 
16 
17 
18 
19 
 
20 
 
21 
 
22 
23 
 
 
 
24    
 
 
 
 
BIS 
 - prepump 
 - intrapump     
 - postpump 
 
CO 
 -prepump 
 -postpump 
 
CI 
 prepu 
 postpu 
 
SVR 
 prepu 
 pstpu 
 
prn thiols 
total thiols 
mal-ald 
prn corbns 
nitrates 
CPB DN 
 
CKMB0 
 
CKMB12 
 
ICUDN 
OTHER 
   
  - postop bld 
 
DRUG 
 
 
 
Bi spectral index 
Prior to CPB 
During CPB 
After CPB 
 
Cardiac output 
Prior to CPB 
After CPB 
 
Cardiac index 
Prior to CPB 
After CPB 
 
Systemic vascular resistance 
Prior to CPB 
After CPB 
 
Protein thiol levels 
Total thiol levels 
Malondialdehyde levels 
Protein carbonyl levels 
Nitrate levels 
Cardiopulmonry bypass duration 
 
Creatinine kinase-MB at 0hr in 
Intensive care stay(ICU) 
Creatinine kinase-mb at 12hrs in 
ICU 
 
Duration of stay in ICU 
Other problems in ICU 
 
Post operative bleeding 
 
Volatile anaesthetic agents used 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 – no problems 
during ICU stay 
1 – Post operative 
bleeding 
1 – Isoflurane 
2 - Sevoflurane 
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Name of the investigator  : Dr. Sathish 
Kumar. D. 
 
Name of the Guide  : Dr. Mary Korula M.D., D.A. 
Topic title: Comparison of cardiac preconditioning effects of 
Isoflurane and Sevoflurane in coronary artery bypass 
surgeries done on cardiopulmonary bypass 
 
Course: Master in Anaesthesiology (Branch X) 
ABSTRACT 
 
BACKGROUND:  
 
Preconditioning by volatile agents is a promising therapeutic strategy to render  
myocardial tissue resistant to perioperative ischemia in cardiac surgery. It was 
hypothesized that preconditioning with volatile anaesthetic agents isoflurane and 
sevoflurane would decrease oxidative stress during ischemic reperfusion injury and  
also prevent postoperative increase in creatinine kinase-MB, a marker of myocardial 
ischemia. But there are only few studies comparing these 2 volatile agents. 
 
AIM:  
 
To compare the cardioprotective properties of Isoflurane and Sevoflurane when used 
before, during and after Cardiopulmonary bypass (CPB) to improve postoperative 
outcome in coronary artery bypass graft surgeries by analyzing: haemodynamic 
parameters such as invasive arterial BP, ECG, cardiac index, systemic vascular 
resistance and CVP; postoperative measurements of CK-MB to compare degree of 
ischemia; biochemical markers of Oxidative and Nitrosative stress at different time 
intervals. 
 
METHODS: 
 
Twenty patients scheduled for CABG surgery on CPB were randomly assigned to 
preconditioning with isoflurane or sevoflurane throughout the surgical procedure. The 
agent used was blinded to surgeons, perfusionist and the biochemist. Biochemical 
markers of oxidative stress (thiols, malondialdehyde, protein carbonyls and nitrates) 
and myocardial ischemia (CK-MB) were determined. Cardiac index (CI) and systemic 
vascular resistance (SVR) were recorded perioperatively. 
 
 
RESULTS:  
 
Both isoflurane and sevoflurane preconditioning showed similar release of oxidative 
stress marker the thiols. Sevoflurane however showed significant reduction of 
malondialdehyde- a marker of lipid peroxidation (P=0.02) and nitrates – a marker of 
nitrosative stress(P=0.03) when compared to isoflurane. No difference in cardiac 
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indices were found between the two groups. Though CK-MB values for patients in 
sevoflurane group were lesser than the iso group, this did not attain statistical 
significance. 
 
CONCLUSION:  
 
Preconditioning with sevoflurane as well as isoflurane preserves myocardial function 
as assessed by biochemical markers in patients undergoing CABG on CPB pump.This 
study demonstrates that  among  these two agents, isoflurane provides more protection 
during the early reperfusion phase,while sevoflurane was effective in  early  
reperfusion as well as in the  immediate post-bypass period, when the oxidative stress 
is much greater. 
 
 
 
 
 
Master Chart
S.NO. HOS NO AGE WT HT NYHA MI PREOP DATA
class prior Bp DM rendys COPD ves_ blk sys dysfn Ef
1 749544c 53 53 168 2 1 nil 0 0 nil 0 0 nil 0 nil 0 4 nil 0 54
2 757681c 55 69 171 2 0 yes-2yrs 1 2 nil 0 0 nil 0 nil 0 2 nil 0 57
3 705336c 50 57 165 2 1 nil 0 0 yes-12yrs 1 12 nil 0 nil 0 2 sys dysfn 1 45
4 741096c 48 48 169 3 1 nil 0 0 nil 0 0 nil 0 nil 0 3 nil 0 44
5 790101c 58 58 172 2 0 yes-5yrs 1 5 nil 0 0 nil 0 nil 0 3 nil 0 56
6 786710c 53 74 169 2 0 yes-10yrs 1 10 yes-1yr 1 1 nil 0 nil 0 3 nil 0 45
7 785206c 53 61 166 2 0 nil 0 0 nil 0 0 nil 0 nil 0 3 nil 0 56
8 801796c 56 54 162 3 0 yes-2yrs 1 2 nil 0 0 nil 0 nil 0 2 nil 0 48
9 814094c 36 54 173 2 0 nil 0 0 nil 0 0 nil 0 nil 0 3 nil 0 59
10 820418c 61 62 165 2 0 yes-10yrs 1 10 yes-9yrs 1 9 nil 0 nil 0 2 nil 0 57
11 817253c 60
12 827061c 51 70 163 2 1 yes-4yrs 1 4 1year 1 1 nil 0 nil 0 3 sysdysfn 1 59
13 819500c 59 46 155 2 1 nil 0 0 nil 0 0 nil 0 nil 0 3 sys dysfn 1 42
14 821391c 34 93 170 3 1 1year 1 1 nil 0 0 nil 0 nil 0 3 sysdysfn 1 41
15 831929c 69 65 175 2 0 nil 0 0 nil 0 0 nil 0 nil 0 3 nil 0 58
16 837665c 56 60 160 2 0 26yrs 1 26 5yrs 1 5 nil 0 nil 0 3 nil 0 59
17 792635c 58 66 155 2 0 nil 0 0 nil 0 0 nil 0 nil 0 3 nil 0 57
18 840192c 64
19 908401B 55 62 166 3 1 yes-1yr 1 1 yes-3yrs 1 3 nil 0 nil 0 3 sys dysfn 1 44
20 819686c 54 56 165 3 1 yes-5yrs 1 5 nil 0 0 nil 0 nil 0 3 sys dysfn 1 41
1
Master Chart
BIS
others hr-base hr-pre hr-post map-base map-pre map-post SPO2 cvp-base cvp-pre cvp-post prepump intrapump postpump
nil 0 80 75 95 88 65 85 100 8 7 9 48 45 51
nil 0 68 75 95 87 65 80 99 11 6 8 51 46 55
nil 0 66 78 89 92 66 70 100 5 7 8 44 46 48
nil 0 60 65 75 86 78 70 100 4 5 8 45 50 43
nil 0 76 88 74 86 78 73 98 10 11 9 44 43 51
MR-fnal 1 56 68 88 75 82 88 100 5 5 8 44 41 48
nil 0 68 75 92 80 65 62 99 8 9 10 42 48 42
hypothy 2 62 69 83 99 80 75 100 3 5 7 42 48 40
nil 0 82 88 95 97 88 79 100 5 8 6 45 48 47
AS-cal 3 68 66 75 88 72 85 98 7 9 6 44 48 48
nil 0 60 85 95 100 72 68 100 7 8 7 44 41 47
MR-fnal 1 132 89 103 90 85 75 98 7 7 6 40 45 50
nil 0 90 98 86 84 85 70 100 6 8 5 44 48 47
nil 0 78 86 95 79 64 72 100 3 5 6 45 48 47
nil 0 65 68 78 88 70 64 100 3 5 5 44 48 50
hypothy 2 66 75 85 88 65 70 99 5 8 9 47 45 41
nil 0 73 85 95 96 85 80 100 6 8 10 48 42 47
MR-fnal 1 68 82 96 56 65 60 98 16 15 12 48 46 40
2
Master Chart
CO CI SVR
prepump postpump prepu postpu prepu pstpu prn thiols totalthiols mal-alde prn corbns nitrates prnthiols totalthiols mal-alde prn corbns
4.5 8.6 2.8 4.9 1205 536 1.03 1.18 0.86 0.32 45.32 0.94 1.24 2.31 0.15
3.47 9.18 2.2 5.1 1220 605 2.12 2.59 1.98 0.17 62.77 1.61 2.18 1.36 0.10
4.11 8.11 2.51 6.1 1105 802 1.41 1.00 2.30 0.20 56.00 1.09 0.85 0.94 0.13
6.25 9.9 3.79 5.59 1234 625 0.41 0.74 2.00 0.23 32.30 0.80 0.56 4.50 0.14
5.8 9.4 2.95 5.3 895 559 2.68 1.71 0.41 0.27 56.44 1.41 2.50 0.21 0.21
5.1 6.75 2.07 4.45 1063 678 3.26 1.18 0.31 0.29 32.22 1.29 0.65 0.52 0.21
4.16 7.42 2.55 4.55 956 610 3.00 2.35 1.67 0.19 38.64 1.09 2.50 0.98 0.16
4.25 7.31 2.71 4.66 1279 416 1.94 1.12 1.96 0.19 32.22 1.67 1.65 1.08 0.11
5.45 12.4 3.32 7.45 980 930 5.06 3.94 3.21 0.31 42.23 1.58 2.56 2.46 0.15
6.31 9.8 3.76 5.84 912 785 4.79 4.97 0.47 0.86 19.55 1.18 1.68 0.75 0.21
4.66 7.17 2.65 4.17 1218 750 0.74 0.24 0.19 0.28 23.56 0.68 1.26 0.38 0.15
5.43 6.48 3.82 4.8 859 512 1.94 1.44 0.86 0.23 23.33 0.94 2.68 0.65 0.17
5.61 10.4 2.75 5.13 811 436 1.35 1.24 0.74 0.34 21.11 0.53 0.82 0.63 0.19
6.86 8.14 3.8 4.55 635 753 1.56 2.53 0.91 0.18 12.45 5.91 5.71 0.91 0.14
3.82 9.25 2.36 5.71 1333 475 0.88 1.00 0.84 0.29 60.00 0.80 1.41 0.32 0.21
4.58 7.12 3.07 4.23 709 649 1.47 2.76 0.92 0.18 19.00 0.94 2.88 1.38 0.11
2.86 7.25 1.65 2.75 1102 689 1.56 2.12 1.12 0.16 14.22 1.12 1.38 1.34 0.13
2.56 6.55 1.6 4.25 1124 589 1.35 1.59 1.23 0.22 17.11 1.41 1.50 1.13 0.12
SAMPLEA SAMPLEB
3
Master Chart
CPBDN
nitrates prnthiols totalthiols mal-alde prn corbns nitrates CKMB_0 CKMB12 ICUDN OTHER DRUG
33.25 0.94 0.62 1.52 0.16 27.26 2:20 27 11 28 po op bld 1 Sevo 2
49.23 0.82 1.82 2.30 0.12 36.61 1:15 28 20 20 nil 0 Iso 1
16.30 0.53 1.00 0.52 0.13 19.07 1:30 15 9 16 nil 0 Sevo 2
22.76 1.24 0.94 1.88 0.17 25.23 1:10 30 17 36 nil 0 Iso 1
34.48 1.59 0.94 0.52 0.18 45.33 1:40 28 27 25 nil 0 Iso 1
34.66 2.03 1.15 0.52 0.22 33.33 1:57 23 16 14 nil 0 Sevo 2
34.66 2.09 3.21 0.69 0.11 31.33 1:40 17 7 20 nil 0 Sevo 2
34.66 1.76 0.32 0.49 0.06 33.33 1:35 21 23 17 nil 0 Iso 1
39.00 1.62 1.35 1.93 0.25 26.88 1:15 18 15 20 nil 0 Iso 1
16.00 2.00 3.35 0.38 0.21 15.12 2:40 57 38 24 nil 0 Sevo 2
18.44 0.29 0.32 0.19 0.43 15.55 1:50 55 69 16 nil 0 Sevo 2
20.00 1.06 2.74 0.75 0.15 26.22 1:50 21 25 22 nil 0 Iso 1
17.35 0.85 1.82 0.58 0.18 16.55 2:00 21 24 18 nil 0 Sevo 2
11.56 1.82 1.59 1.08 0.11 14.66 1:40 14 28 19 nil 0 Iso 1
46.61 0.71 1.35 0.86 0.21 45.78 2:10 23 28 18 nil 0 Iso 1
19.00 1.15 1.44 0.97 0.14 14.86 1:20 29 20 21 nil 0 Sevo 2
16.88 1.85 2.06 1.96 0.15 8.88 2:50 31 39 23 nil 0 Iso 1
27.77 1.12 1.94 1.37 0.17 17.11 3:10 84 60 20 nil 0 Sevo 2
SAMPLEC
4
